Nicolai Maass1, Helmut Ostermann2, Kurt Possinger3, Peter Klein4, Hans Tesch5, Lars Mühlenhoff6, Dirk Bauerschlag1. 1. Klinik für Gynäkologie und Geburtshilfe, UKSH, Kiel. 2. Medizinische Klinik und Poliklinik III, Klinikum der Universität München-Großhadern, München. 3. Medizinische Klinik mit Schwerpunkt Onkologie und Hämatologie, Charité Campus Mitte, Berlin. 4. d.s.h. Statistical Services GmbH, Rohrbach. 5. Onkologische Gemeinschaftspraxis, Frankfurt/M. 6. Medical Affairs, AstraZeneca, Wedel, Germany.
Abstract
BACKGROUND: Endocrine therapy is recommended for the treatment of postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC). METHODS: ACT-FASTER was a German prospective non-interventional cohort study in postmenopausal women with HR+ ABC receiving fulvestrant 500 mg as first line (1 L), second line (2 L) or third line (3 L), or exemestane (any line) in the real-world palliative setting. Primary study objectives included the effectiveness of fulvestrant according to line of palliative treatment measured by time to progression (TTP), and real-life data on the epidemiology and management of these patients. RESULTS: Of 498 evaluable patients (mean age 67.5 years), 99% were estrogen receptor-positive. On study, 86.7% of patients received fulvestrant 500 mg and 13.3% exemestane. Median TTP was 9.7 months in patients receiving fulvestrant 1 L; 6.8 months for 2 L; and 6.7 months for 3 L. The comparison between fulvestrant 1 L palliative treatment and 2 L or 3 L showed that early initiation of treatment prolonged TTP (hazard ratio 1.26; 95% confidence interval 1.08-1.48). Treatments were well tolerated. CONCLUSION: Fulvestrant 500 mg was administered successfully to patients under daily practice conditions, and both medications were well tolerated. TTP was longest in patients treated with fulvestrant 500 mg 1 L compared with 2 L and 3 L in the palliative care setting.
BACKGROUND: Endocrine therapy is recommended for the treatment of postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC). METHODS: ACT-FASTER was a German prospective non-interventional cohort study in postmenopausal women with HR+ ABC receiving fulvestrant 500 mg as first line (1 L), second line (2 L) or third line (3 L), or exemestane (any line) in the real-world palliative setting. Primary study objectives included the effectiveness of fulvestrant according to line of palliative treatment measured by time to progression (TTP), and real-life data on the epidemiology and management of these patients. RESULTS: Of 498 evaluable patients (mean age 67.5 years), 99% were estrogen receptor-positive. On study, 86.7% of patients received fulvestrant 500 mg and 13.3% exemestane. Median TTP was 9.7 months in patients receiving fulvestrant 1 L; 6.8 months for 2 L; and 6.7 months for 3 L. The comparison between fulvestrant 1 L palliative treatment and 2 L or 3 L showed that early initiation of treatment prolonged TTP (hazard ratio 1.26; 95% confidence interval 1.08-1.48). Treatments were well tolerated. CONCLUSION: Fulvestrant 500 mg was administered successfully to patients under daily practice conditions, and both medications were well tolerated. TTP was longest in patients treated with fulvestrant 500 mg 1 L compared with 2 L and 3 L in the palliative care setting.
Authors: Irene Kuter; Julia M W Gee; Roberto Hegg; Christian F Singer; Rajendra A Badwe; Elizabeth S Lowe; Ugochi A Emeribe; Elizabeth Anderson; Francisco Sapunar; Pauline Finlay; Robert I Nicholson; José Bines; Nadia Harbeck Journal: Breast Cancer Res Treat Date: 2012-05 Impact factor: 4.872
Authors: M Kaufmann; E Bajetta; L Y Dirix; L E Fein; S E Jones; N Zilembo; J L Dugardyn; C Nasurdi; R G Mennel; J Cervek; C Fowst; A Polli; E di Salle; A Arkhipov; G Piscitelli; L L Miller; G Massimini Journal: J Clin Oncol Date: 2000-04 Impact factor: 44.544
Authors: Antonio Llombart-Cussac; Amparo Ruiz; Antonio Antón; Agustí Barnadas; Silvia Antolín; José E Alés-Martínez; Isabel Alvarez; Raquel Andrés; José A García Saenz; Juan Lao; Eva Carrasco; Carmen Cámara; Isabel Casas; Miguel Martín Journal: Cancer Date: 2011-06-29 Impact factor: 6.860
Authors: Robert J Paridaens; Luc Y Dirix; Louk V Beex; Marianne Nooij; David A Cameron; Tanja Cufer; Martine J Piccart; Jan Bogaerts; Patrick Therasse Journal: J Clin Oncol Date: 2008-09-15 Impact factor: 44.544
Authors: Stephen Chia; William Gradishar; Louis Mauriac; Jose Bines; Frederic Amant; Miriam Federico; Luis Fein; Gilles Romieu; Aman Buzdar; John F R Robertson; Adam Brufsky; Kurt Possinger; Pamela Rennie; Francisco Sapunar; Elizabeth Lowe; Martine Piccart Journal: J Clin Oncol Date: 2008-03-03 Impact factor: 44.544
Authors: Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi Journal: N Engl J Med Date: 2012-08-02 Impact factor: 91.245
Authors: Giorgia Zucchini; Elena Geuna; Andrea Milani; Caterina Aversa; Rossella Martinello; Filippo Montemurro Journal: Int J Womens Health Date: 2015-05-27